Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected autologous hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- University Hospital Tuebingen
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ selected autologous hematopoietic stem cells is an autologous cell therapy used in hematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases, primarily systemic sclerosis (SSc). The therapeutic process involves mobilizing the patient's own hematopoietic stem cells from the peripheral blood, collecting them via apheresis, and performing positive selection for CD34+ cells using immunomagnetic bead technology (such as the CliniMACS system). This selection process enriches the graft for progenitor cells while depleting mature, autoreactive T-cells and other immune effectors. Following high-dose conditioning chemotherapy (typically cyclophosphamide) to ablate the patient's dysregulated immune system, the purified CD34+ cells are reinfused to 'reset' the immune response and promote the development of a new, self-tolerant immune repertoire. This approach is being investigated by institutions like University Hospital Tuebingen to optimize treatment outcomes and reduce treatment-related mortality in patients with progressive systemic sclerosis.
- Other names
- CD34+ selected autologous HSCTpurified autologous CD34+ hematopoietic stem cellsCD34+ selected autologous hematopoietic progenitor cells
Beyond the preview
Go deeper on CD34+ selected autologous hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ selected autologous hematopoietic stem cells.